IncobotulinumtoxinA in Esthetics
June 2013 | Volume 12 | Issue 6 | Original Article | e111 | Copyright © 2013
Martina Kerscher MD,a Yana Yutskovskaya MD,b and Timothy Corcoran Flynn MDc
aDivision of Cosmetic Sciences, Department of Chemistry, University of Hamburg, Hamburg, Germany
bDepartment of Dermatovenereology and Cosmetology, Vladivostok State Medical University, Vladivostok, Russia
cDepartment of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical Director,
Cary Skin Center, Cary, NC
IncobotulinumtoxinA (Xeomin®/Xeomeen®/Bocouture®/XEOMIN Cosmetic™) is a botulinum toxin type A that differs from other commercially
available botulinum toxin type A preparations in that it is free from complexing proteins ([150 kDa]/NT 201). The proven efficacy
of incobotulinumtoxinA in various therapeutic indications preceded its use in the field of esthetic medicine, where it is widely approved
for the treatment of glabellar frown lines on the basis of positive efficacy and safety findings from a number of clinical trials. Here, we
discuss the characteristics of incobotulinumtoxinA and review the clinical data supporting its use in esthetics.
J Drugs Dermatol. 2013;12(6):e111-e120.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Characteristics of IncobotulinumtoxinA
IncobotulinumtoxinA (Xeomin®/Xeomeen®/Bocouture®/XEOMIN Cosmetic™; Merz Pharmaceuticals GmbH, Germany), along with onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic/Vistabel®; Allergan, Irvine, CA, USA) and abobotulinumtoxinA (Dysport®; Ipsen Ltd, Slough, Berkshire, UK / Azzalure®; Galderma UK Ltd, Watford, Hertfordshire, UK), is derived from the Hall strain of the anaerobic bacterium Clostridium botulinum type A. However, incobotulinumtoxinA is a formulation of botulinum neurotoxin type A that has undergone a purification processes that separates the 150-kDa neurotoxin from the high-molecular-weight (900 kDa) complex.1,2 Therefore, the active ingredient of incobotulinumtoxinA represents the pure neurotoxin (150 kDa) that is free from complexing proteins.1 In this respect, incobotulinumtoxinA differs from onabotulinumtoxinA and abobotulinumtoxinA, which both contain complexing proteins. IncobotulinumtoxinA is licensed in the United States, Canada, all major European countries, Argentina, and South Korea for the treatment of glabellar frown lines (GFL); in Russia and Mexico it is licensed for the treatment of mimic wrinkles and hyperkinetic facial lines, respectively.
In a study by Frevert to determine the amount of neurotoxin present in pharmaceutical preparations of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, the mean concentrations were observed to be 0.44 ng/100 U, 0.73 ng/100 U, and 0.65 ng/100 U, respectively. IncobotulinumtoxinA contains no other clostridial proteins, and, therefore, the specific biologic potency relative to the total foreign protein is 227 U/ng. Since the reported clostridial protein content per 100 U of onabotulinumtoxinA is 5 ng and of abobotulinumtoxinA is 0.87 ng, the equivalent specific biologic potency relative to the total foreign-protein load for onabotulinumtoxinA is 20 U/ng and for abobotulinumtoxinA is 115 U/ng.3 Thus, the foreign-protein load delivered per unit of incobotulinumtoxinA is lower than that for both onabotulinumtoxinA and abobotulinumtoxinA.
Complexing proteins protect the neurotoxin from harsh environmental conditions (such as low gastric pH) after oral ingestion.4,5 However, whether or not they are useful in commercially available preparations of botulinum neurotoxin serotype A (BoNT/A) is disputed as complexing proteins play no role in the clinical or therapeutic efficacy of BoNT/A. In real-time and accelerated-stability studies, incobotulinumtoxinA was stable without refrigeration for 48 months and was unaffected by short-term temperature stress up to 60°C, suggesting that a role for complexing proteins in stabilizing the neurotoxin outside the intestine is unlikely.6 Furthermore, rapid dissociation of the BoNT/A complexes in onabotulinumtoxinA and abobotulinumtoxinA occurs at a neutral physiological pH, with a release of up to 80% of neurotoxin within 1 minute at neutral pH.7 Such rapid dissociation at normal physiologic pH suggests that the complexing proteins cannot protect the neurotoxin postinjection, or limit its spread.
Spread of Effect/Field of Efficacy
The spread of different BoNT/A preparations is of crucial clinical relevance, especially in esthetics, where precise localization of the clinical effect is essential to avoid adverse events (AEs) caused by movement beyond the target muscle.8 Six weeks after injection of dosages in line with those recommended for the treatment of GFL,9-11 the mean maximal areas of anhidrosis (indicating the size of the field of efficacy) for incobotulinumtoxinA (5 U), onabotulinumtoxinA (5 U), and abobotulinumtoxinA (12.5 U) were 364.3 ± 138.1, 343.1 ± 110.7, and 459.1 ± 151.8 mm2, respectively.8 The maximal area of anhidrosis for inco-